Sailfish Therapeutics | Stuart Therapeutics

Scott Baratta

Consultant/Advisor

$3.7B

DED Market Size, 7 Major Markets (2023)

$9B+

Projected Global Market by 2030

30M+

U.S. Adults Affected by Dry Eye Disease

FoundedStuart Therapeutics was founded in Stuart, Florida, with the PolyCol collagen mimetic peptide platform as its founding technology. The company is named for its hometown. Co-founder Dr. Robert O. Baratta, whose name appears in the company's Phase II publication authorship, passed away in September 2024. The company's WHO WE ARE section notes each founder was personally affected by chronic eye disease.

Scale11 to 50 employees. Privately held. $11M raised in a Series A round led by InFocus Capital Partners and WARF. Partnerships include Glaukos (glaucoma neuroprotection license), Aju Pharm Co, Ora, Vanderbilt University, and the University of Rochester. Headquartered at 2336 SE Ocean Blvd, Suite 373, Stuart, FL.

Key signalST-100 (vezocolmitide) showed improvement in both signs and symptoms within two to four days in Phase III, a speed of onset that no currently approved dry eye therapy matches. The Phase III missed its primary endpoint but the speed-of-onset finding is the clinical differentiator the company is now building its next study around.

The 7 on 7+ Assessment

7 on 7+ Score

Website Score

16 / 49

Website effectiveness as evidence of leadership thinking — 7 criteria, each scored 1–7. Build on methodology developed by Alan Power & Gair Maxwell.

IDEA Score

11 / 49

Power of your complete digital presence, including social, search, gen-AI - to generate PULL.

Website Score

Tracks your website effectiveness.

IDEA Adjustment

Adjusts for your complete digital footprint.

7 on 7+ Score

Your legend-building signal.

Category Leader

Noveome Biotherapeutics

Website

IDEA

Noveome leads in follower count at 4,817 on LinkedIn, posts more frequently than Stuart, and has a multi-channel presence including Facebook and Instagram, though Instagram has only 12 followers and 2 posts; content is milestone-driven and NEC-focused rather than ophthalmology-oriented.

Executive Takeaway

Stuart Therapeutics has built a scientifically credible clinical-stage platform with a genuinely distinctive premise: healing the ocular surface by repairing damaged collagen rather than suppressing inflammation or stimulating tears. The company has Phase III data, earned media coverage in major ophthalmology publications, and a growing roster of key opinion leaders. Scott Baratta, serving as Consultant/Advisor since January 2024, brings a Wharton-trained finance and operations background to a company navigating its next capital and regulatory chapter. The digital signal tells a consistent story: strong scientific credibility, low brand volume, and no IDEA that has yet been named and deployed in the market. The opportunity is to answer the B.H.O.Q. before the next phase of development forces the brand to compete on clinical data alone.

Website Score — By Criterion

Seven criteria, each scored 1–7 by Alan Power and Gair Maxwell. The sum is your website score out of 49. Vistage room average: 13–14. A score above 20 is genuinely strong.

First Impression

Immediate 2-3 sec WOW factor. Instant clarity on who this brand speaks to.

The homepage opens with the tagline 'Preserving Your Future' and two large navigation tiles: Our Pipeline and Our Focus. Purpose is identifiable within two to three seconds: a clinical-stage ocular biotech with a collagen-repair platform. Nothing stops a visitor or creates curiosity beyond the tagline. The entry is cleaner than most clinical-stage sites but not distinctive.

Impact

Signature homepage video. Genuine human connection, cinematic and story-based.

No video is present on the homepage or any other page reviewed. The site relies on static photography, tile graphics, and headshot portraits throughout. A first-time visitor encounters no motion, no story in motion, and no emotional pull from the visual layer.

Originality

Highly distinctive identity. Instantly recognizable. Not a template.

The PolyCol platform is named and the collagen-repair premise is stated directly: 'healing through the restoration of disease-damaged collagen.' The About page includes a WHO WE ARE section noting that each founder has been personally affected by chronic eye disease. That is a distinctive and human anchor. The site's template design does not match the distinctiveness of the underlying scientific claim.

Culture

Video evidence from real people indicating a destination employer. Not a values list.

The WHO WE ARE section includes a memorial to co-founder Dr. Robert O. Baratta and notes founders were personally motivated by chronic eye disease. This is the most human moment on the site. No team video, no employee voice content, and no values page exists. The scientific advisory board and board of directors are listed with bios but without personal story.

Consistency

Track record of publishing current, original content across platforms.

A News section exists and was active in the past. Post dates range from July 2025 back through 2023, with a cadence of roughly four to six posts per year. All content is milestone-driven: trial completions, publication announcements, conference presentations, and board appointments. A visitor landing on the News page would see a company that publishes when something happens, not one that publishes to teach.

Audience Reach

Numbers indicating a growing community. Evidence of genuine engagement.

The site navigation is structured for investors, researchers, and clinical partners: Pipeline, About, Team, SAB, Board, News. No audience-specific copy or CTAs aimed at physicians or patients. The partnership list (Glaukos, WARF, Vanderbilt, University of Rochester, Ora) signals the company is speaking to a sophisticated scientific and financial audience.

Visuals

Cohesive visual elements reflecting brand spirit. Distinctive design language.

The site uses a blue and white palette with a distinctive geometric lattice logo mark. Photography is professional and clinical in tone. The overall design is clean but reads as a standard template for clinical-stage biotech. The logo is the most visually original element on the site.

IDEA Score — The Signal Before the Click

How You Show Up in the World

The IDEA Score measures what happens before someone reaches your website — the off-site signal that shapes perception from the first search, the LinkedIn scroll, the founder post.

out of 49

IDEA Score — Digital Footprint

The Idea That Changes Everything

Seven axes. Each one measures a different dimension of how your off-site signal lands — not what your website says, but what the world hears before anyone clicks your URL.

Pull vs. push. Category of one vs. category of many. A founder voice vs. a corporate signal. These are the levers that determine whether a prospect arrives already interested — or arrives already skeptical.

Pull vs. Push

Content creates gravity vs. broadcast/promotional

The LinkedIn post asking 'What if treating dry eye isn't about suppressing inflammation or stimulating tears? What if the answer begins with repairing the ocular surface?' is the single pull-oriented moment in the visible content set. Every other post is a push: conference notices, publication announcements, and milestone press releases. That one framing question, posted two weeks ago, got 14 reactions and no comments, which suggests it landed but is not yet a pattern.

ONLY vs. Category

Proprietary language/named POV vs. sounds like every competitor

The collagen-repair premise is genuinely category-distinct. The language of repair versus suppression differentiates. That language appears in one LinkedIn post and in the LinkedIn About overview. It is present but not deployed consistently enough to be what the audience associates with Stuart Therapeutics.

Audience Building

Clear who it's for AND building following beyond buyers

274 LinkedIn followers. No evidence of deliberate audience growth activity: no follow CTAs, no content designed for sharing, no community targeting. The audience is whoever found the page, not one Stuart has actively built. Scott Baratta has 610 followers and reposts Stuart content, which adds modest reach.

Different-er vs. Better

Competes on distinctiveness/belief vs. features/specs/price

The company competes on difference at the scientific level: a first-in-class collagen mimetic peptide platform treating a root cause rather than a symptom. In social content, that distinction surfaces only in the one framing post and in the company overview. The rest of the content competes on proof of progress, which is milestone-driven and interchangeable with any other clinical-stage biotech.

IDEA vs. Best Practices

Organizing belief visible across all channels vs. channel-by-channel

No through-line connects the channels. The website carries the collagen-repair premise in the About text. LinkedIn posts it once in a framing question. Conference and publication content mirrors what any clinical-stage company would post. Scott Baratta's reposts amplify company announcements without adding a personal POV. Each channel does what that channel does.

Founder/Leader Voice

Named human with consistent opinionated first-person presence

Eric Schlumpf, President and CEO, appears at industry conferences including JPM Healthcare 2026, OIS Dry Horizons, Eyecelerator at AAO, and AECOS. He is named and visible in earned media. His LinkedIn posts are tied to company milestones and conference appearances. No first-person perspective content or recurring POV is visible. Scott Baratta's LinkedIn activity is repost-only with no original voice.

Cultural Relevance

Signal connects to a larger shift in the world vs. exists in isolation

The company's content does not connect to a larger conversation about vision loss, patient experience, or the limits of existing dry eye treatments. Posts are self-referential: milestones, publications, and conference appearances. The personal motivation of the founders, each affected by chronic eye disease, is present on the website but has not appeared in social content.

Digital Footprint Scan

Where You're Showing Up — and Where You're Not

Company Website (stuarttherapeutics.com)

Active

A clinical-stage biotech site with full navigation: Pipeline, About, Team, SAB, Board, and News. The site carries the collagen-repair premise, a memorial to co-founder Dr. Robert Baratta, and a roster of scientific advisors from Vanderbilt, Duke, Cleveland Clinic, and MIT. A buyer who arrives and digs will find credibility. A buyer who scans will find a standard template with a distinctive logo.

Company LinkedIn (Stuart Therapeutics)

Weak

274 followers. Posts roughly monthly. Content is milestone-driven: conference announcements, publication shares, KOL podcast reshares. The most recent post asked a genuine question about dry eye treatment philosophy. Engagement averages 8 to 15 reactions per post, with a high of 42 for an Eyecelerator feature. No consistent voice or through-line.

Scott Baratta LinkedIn

Weak

610 followers. Activity is repost-only: Stuart Therapeutics Phase III results, CMP publication announcements, and Eric Schlumpf content. One original post about a Sailfish Therapeutics collagen mimetic peptides article. No first-person perspective content visible. Presence functions as a signal amplifier, not an independent voice.

Instagram

Absent

No Stuart Therapeutics Instagram account found. Sailfish Therapeutics has no operable website or social presence. Scott Baratta has no confirmed Instagram presence.

Facebook

Absent

No Stuart Therapeutics Facebook page found. No confirmed Facebook presence for Scott Baratta.

YouTube

Absent

No owned Stuart Therapeutics YouTube channel found. CEO Eric Schlumpf appears in third-party video on OIS, Eyewire, and Onyx Newsroom, but no owned channel exists.

Industry Events and Publications

Active

Stuart Therapeutics has been featured in Healio, The Ophthalmologist, Eyewire/Eyecelerator, OIS podcast, and Onyx Newsroom. CEO Eric Schlumpf presented at JPM Healthcare 2026, OIS Dry Horizons in Seattle, AAO Eyecelerator in Orlando, and AECOS 2025 in Deer Valley. Phase III results published June 2025. CMP peer-reviewed study published in Pharmaceuticals July 2025. Sailfish Therapeutics has no confirmed public presence beyond a coming soon website.

Strategic Opportunity

How to Build Your Legend

Short Term (0–6 months)

One Month to the IDEA

The B.H.O.Q. for Stuart Therapeutics is sitting in plain sight: why has treating dry eye disease for decades missed the point, and what does it actually mean to heal it? A sprint to uncover and articulate the IDEA, the one thing Stuart will be the only for, would give every conference appearance, press release, and LinkedIn post a true north. The collagen-repair premise is already the most category-distinct claim in dry eye. It needs a signature story and a line the market can repeat.

Surface the founding story

The signature story is already on the website: each founder was personally affected by chronic eye disease. That is the human entry point that earns the right to all the science that follows. It is buried in the About page. Before any other identity work begins, that story belongs at the front door. Moving it to the homepage costs nothing and changes the emotional register of everything a visitor experiences next.

Start the different-er content cadence

The LinkedIn post asking 'What if treating dry eye isn't about suppressing inflammation?' got 14 reactions and earned attention in a field where most posts get four. That post is the prototype for a different-er content cadence: one teaching post per month that advances the collagen-repair premise in plain language, not a press release. Different-er content is what earns reposts from KOLs and builds the audience Stuart does not yet have.

Medium Term (6–18 months)

IDEA to Iconic Identity

Once the IDEA is named and the signature story is live, Stuart needs the full identity system: category language clean-up, message hierarchy with proof points, and a visual system that matches the distinctiveness of the science. The logo mark is the strongest asset on the site today. The design execution around it is template-level. An identity that makes 'repair, not manage' visible at every touchpoint would make every earned media appearance, every conference slide, and every investor deck land with more force.

IDEA to Brand-Driven Growth: build the KOL amplification system

Stuart already has the relationships: Glaukos, Ora, Vanderbilt, the OIS and Eyecelerator networks, and a growing roster of scientific advisors and key opinion leaders. Those relationships are the distribution system. Aligning marketing and content so KOLs have a framing they can repeat, and a simple way to amplify the collagen-repair premise, would bend the curve on reach without building a new audience from scratch. The Eyecelerator post got 42 reactions because someone else's platform carried Stuart's story. That system needs to be deliberate.

IDEA to Media Company: owned video

Eric Schlumpf presents at JPM Healthcare, OIS Dry Horizons, AAO, and AECOS. None of those appearances live on an owned channel. A quarterly video, short-form, explaining why repairing collagen changes the treatment equation, would give the brand a repeatable presence that compounds. One video per quarter is not a media company. It is the beginning of one. In a category this specialized, a company that teaches consistently at low volume will eventually own the conversation that everyone else is just participating in.

Competitive Landscape

Who's in the Conversation

Aldeyra Therapeutics

CLINICAL-STAGE DRY EYE / NDA STAGE

A Nasdaq-listed clinical-stage biotech developing reproxalap, a first-in-class RASP modulator for dry eye disease. The company received a third complete response letter from the FDA in March 2026 after multiple NDA submission cycles. Publicly traded with approximately $101M in cash reported at year-end 2024. Website is investor-forward with a named platform but no human or patient-oriented content.

Palatin Technologies

CLINICAL-STAGE DRY EYE / PHASE 3 MISS

A Nasdaq-listed biopharmaceutical company developing PL9643, a melanocortin receptor agonist for dry eye disease. The Phase 3 MELODY-1 trial missed its primary sign endpoint in February 2024, dropping the stock roughly 40%. The company is publicly traded on NYSE American and has an investor-relations-driven digital presence with minimal brand narrative.

Noveome Biotherapeutics

CLINICAL-STAGE PLATFORM / COMPARABLE SIZE

A Pittsburgh-based clinical-stage biotech developing ST266, a secretome platform biologic, primarily for necrotizing enterocolitis. Raised a Series E financing round in 2025. Has 4,817 LinkedIn followers and posts roughly monthly, but content is almost entirely focused on NEC rather than ophthalmology. Instagram has 12 followers and 2 posts. Digital presence is more active than Stuart's in volume but equally announcement-driven in content.

The category has no brand

COMPETITIVE ADVANTAGE

Every clinical-stage dry eye company in this space competes on regulatory milestones and scientific credentials. None has named an IDEA, built an audience, or claimed a belief the market can repeat. Stuart has the most differentiated scientific premise in the category: repairing the thing that is actually damaged rather than managing the symptoms of damage. No competitor has claimed that story. The company that names it, teaches it consistently, and earns the right to it in public channels first will define the category for everyone who comes after.

Market Context

The Industry Around You

The dry eye disease treatment market was valued at approximately $3.7 billion across seven major markets in 2023, with the United States accounting for roughly 73% of that total. The global market is projected to cross $9 billion by 2030 at a compound annual growth rate driven by aging populations, increased screen time, and a growing pipeline of novel therapeutics beyond currently approved anti-inflammatory agents. Approximately 30 million U.S. adults are affected by dry eye disease, with roughly 16 million having a formal diagnosis.

$3.7B

DED Market Size, 7 Major Markets (2023)

DelveInsight, 2025

$9B+

Projected Global Market by 2030

DelveInsight, 2024

30M+

U.S. Adults Affected by Dry Eye Disease

Stuart Therapeutics Phase III press release, June 2025

54.6M

Diagnosed DED Cases, 7 Major Markets (2023)

DelveInsight, 2025

What Keeps You Up at Night

The forces shaping Sailfish Therapeutics | Stuart Therapeutics's competitive environment — and why standing still is not an option.

⚡

Regulatory path requires a second Phase III

The June 2025 Phase III results for ST-100 (vezocolmitide) missed the primary endpoint. The company announced findings would guide design of a second Phase III study. That means more time, more capital, and a longer road to NDA submission. In a category where Aldeyra has been navigating FDA cycles for years, the timeline risk is real and investor patience is not unlimited.

Headwind

⚡

Capital requirements at a pre-revenue stage

Stuart Therapeutics has raised $11M in a Series A led by InFocus Capital and WARF. Clinical trials, manufacturing partnerships, and regulatory work are expensive. The company is privately held with no confirmed subsequent fundraise. Scott Baratta's role preparing financial statements and contributing to financial strategy suggests the company is actively managing its capital position through the next development phase.

Headwind

⚡

Category noise from approved and near-approved competitors

Restasis, Xiidra, and Vevizye are already on market. Aldeyra's reproxalap is under FDA review with a PDUFA date of March 2026. A prescribing physician's attention is finite. A company without an owned brand story risks being categorized as another molecule in development rather than a genuinely different approach to the disease.

Headwind

Where the Opportunity Lives

The same forces creating pressure are also creating openings for firms willing to lead.

🎯

Unmet need persists despite approved therapies

Millions of dry eye disease patients remain symptomatic on current therapies. Restasis and Xiidra address inflammation but do not repair the underlying surface damage. A therapy that works by a different mechanism, especially one showing signs and symptoms improvement within two to four days, addresses a real gap that physicians and patients can feel.

Stuart Therapeutics Phase III press release, June 2025 Tailwind

🎯

Platform breadth extends the asset value

The PolyCol collagen mimetic peptide platform has applications beyond dry eye: glaucoma neuroprotection (licensed to Glaukos), myopia, dry AMD, and corneal wound healing. An exclusive worldwide license for the glaucoma asset is already in place. That breadth means a successful dry eye NDA is not the only value driver in the company.

Stuart Therapeutics company website and press releases, 2023-2025 Tailwind

🎯

Growing clinical recognition in the ophthalmology community

Stuart Therapeutics has been featured at Eyecelerator at AAO, OIS Dry Horizons, JPM Healthcare 2026, and AECOS 2025. Peer-reviewed publications in Pharmaceuticals and Ophthalmology Science provide scientific credibility that KOLs reference. The Ophthalmologist ran a feature on collagen's emerging role in dry eye therapy specifically citing the research underpinning Stuart's approach.

The Ophthalmologist, 2025; Eyewire/Eyecelerator coverage, 2025 Tailwind

🔒

Unlock Your Full Roadmap

Your Future-State Brand Expression

We've built a vision of what Sailfish Therapeutics | Stuart Therapeutics could look like — a reimagined digital presence that matches the caliber of the operation behind it. Your full 7 on 7+ Score & Analysis includes:

Phase 1

Brand Identity Strategy

Clarify positioning, origin story, and visual identity to match the caliber of the operation, people, and relationships the company has actually built.

Phase 2

Brand Amplification Strategy

Build the content engine, thought leadership, and social presence that makes Sailfish Therapeutics | Stuart Therapeutics impossible to ignore in a category being reshaped in real time.

Phase 3

Media & Distribution Strategy

Launch the channels, campaigns, and conversion architecture that turn visibility into relationships and position Sailfish Therapeutics | Stuart Therapeutics as a category-defining brand.

Yes, I Want to Build a Legendary Brand. Let's Move to the Next Step.